SCYNEXIS, Inc. (SCYX)
NASDAQ
Market Cap
$75.94M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
742 of 809
Rank in Industry
45 of 53
Largest Insider Buys in Sector
SCYX Stock Price History Chart
SCYX Stock Performance
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Insider Activity of SCYNEXIS, Inc.
Over the last 12 months, insiders at SCYNEXIS, Inc. have bought $0 and sold $0 worth of SCYNEXIS, Inc. stock.
On average, over the past 5 years, insiders at SCYNEXIS, Inc. have bought $350,055 and sold $4.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 75,000 shares for transaction amount of $225,000 was made by Taglietti Marco (Chief Executive Officer) on 2022‑04‑26.
List of Insider Buy and Sell Transactions, SCYNEXIS, Inc.
| 2022-04-26 | Taglietti Marco | Chief Executive Officer | 75,000 0.226% | $3.00 | $225,000 | -8.26% | ||
| 2022-04-26 | Sukenick Scott | General Counsel | 3,500 0.0105% | $3.00 | $10,500 | -8.26% | ||
| 2021-01-22 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 319,000 1.2567% | $8.24 | $2.63M | -12.08% | |
| 2021-01-21 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 95,000 0.3717% | $7.38 | $701,100 | -2.46% | |
| 2021-01-20 | Sale | PERCEPTIVE ADVISORS LLC | 10 percent owner | 185,000 0.717% | $7.43 | $1.37M | -3.77% | |
| 2020-12-21 | Taglietti Marco | Chief Executive Officer | 40,000 0.3797% | $6.25 | $250,000 | +18.08% | ||
| 2020-12-21 | Angulo Gonzalez David | Chief Medical Officer | 1,600 0.0152% | $6.25 | $10,000 | +18.08% | ||
| 2020-12-21 | Macdonald Guy | director | 8,000 0.0759% | $6.25 | $50,000 | +18.08% | ||
| 2020-12-21 | Francois Eric | Chief Financial Officer | 600 0.0057% | $6.25 | $3,750 | +18.08% | ||
| 2020-12-21 | Sukenick Scott | General Counsel | 1,600 0.0152% | $6.25 | $10,000 | +18.08% | ||
| 2020-12-21 | Tinmouth Brian Philippe | director | 8,000 0.0759% | $6.25 | $50,000 | +18.08% | ||
| 2020-12-21 | ANIDO ARMANDO | director | 5,000 0.0475% | $6.25 | $31,250 | +18.08% | ||
| 2020-12-21 | GILMAN STEVEN C | director | 4,000 0.038% | $6.25 | $25,000 | +18.08% | ||
| 2020-12-21 | HANHAM ANN | director | 3,200 0.0304% | $6.25 | $20,000 | +18.08% | ||
| 2019-12-12 | Taglietti Marco | Chief Executive Officer | 333,334 0.461% | $1.00 | $333,334 | -0.94% | ||
| 2019-08-21 | Taglietti Marco | Chief Executive Officer | 19,000 0.0171% | $0.56 | $10,545 | -19.28% | ||
| 2019-08-20 | Taglietti Marco | Chief Executive Officer | 1,000 0.0009% | $0.56 | $555 | -19.19% | ||
| 2019-08-15 | Taglietti Marco | Chief Executive Officer | 20,030 0.0349% | $1.01 | $20,230 | -12.98% | ||
| 2019-04-17 | Taglietti Marco | Chief Executive Officer | 50,000 0.095% | $1.63 | $81,500 | -32.30% | ||
| 2019-01-10 | Taglietti Marco | Chief Executive Officer | 50,000 0.1029% | $0.69 | $34,500 | +70.59% |
Insider Historical Profitability
9.39%
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 1800000 4.8377% | $2.01 | 0 | 3 | |
| ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 1240575 3.3342% | $2.01 | 1 | 0 | |
| Ventech Capital II | 10 percent owner | 414211 1.1132% | $2.01 | 1 | 0 | |
| Nothias Jean-Yves | director | 295077 0.7931% | $2.01 | 1 | 0 | |
| FCPR Biotechnology Fund | 10 percent owner | 295077 0.7931% | $2.01 | 1 | 0 | |
| Taglietti Marco | Chief Executive Officer | 272068 0.7312% | $2.01 | 30 | 0 | +4.55% |
| F.C.P.R. Genavent | 10 percent owner | 237598 0.6386% | $2.01 | 1 | 0 | |
| Machado Patrick | director | 60000 0.1613% | $2.01 | 2 | 0 | +14.14% |
| Sukenick Scott | General Counsel | 53499 0.1438% | $2.01 | 3 | 0 | +0.4% |
| HASTINGS DAVID C | director | 31834 0.0856% | $2.01 | 2 | 0 | <0.0001% |
| Angulo Gonzalez David | Chief Medical Officer | 23780 0.0639% | $2.01 | 11 | 0 | +18.39% |
| Macdonald Guy | director | 12000 0.0323% | $2.01 | 2 | 0 | +25.4% |
| Francois Eric | Chief Financial Officer | 11732 0.0315% | $2.01 | 3 | 0 | +14.06% |
| Tinmouth Brian Philippe | director | 8000 0.0215% | $2.01 | 1 | 0 | +18.08% |
| ANIDO ARMANDO | director | 5000 0.0134% | $2.01 | 1 | 0 | +18.08% |
| GILMAN STEVEN C | director | 4000 0.0108% | $2.01 | 1 | 0 | +18.08% |
| HANHAM ANN | director | 3622 0.0097% | $2.01 | 2 | 0 | +5.55% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| Federated Hermes | $6.2M | 11.16 | 4.21M | -12.28% | -$867,300.00 | 0.01 | |
| Kingdon Capital Management | $3.29M | 5.92 | 2.24M | 0% | +$0 | 0.44 | |
| The Vanguard Group | $2.48M | 4.47 | 1.69M | +8.29% | +$189,854.92 | <0.0001 | |
| Avidity Partners Management Lp | $2.13M | 3.84 | 1.45M | 0% | +$0 | 0.08 | |
| Amh Equity Ltd | $970,200.00 | 1.75 | 660,000 | +19.91% | +$161,112.00 | 1.21 | |
| Bank of America | $855,298.00 | 1.54 | 581,835 | +145.84% | +$507,382.59 | <0.0001 | |
| D.A. Davidson Companies | $770,966.00 | 1.39 | 524,467 | -0.38% | -$2,973.81 | 0.01 | |
| Acadian Asset Management | $618,000.00 | 1.12 | 421,083 | +5.43% | +$31,847.88 | <0.01 | |
| Bridgeway Capital Management | $581,994.00 | 1.05 | 395,914 | +46.55% | +$184,852.63 | 0.01 | |
| Renaissance Technologies | $524,000.00 | 0.94 | 356,240 | +54.26% | +$184,306.09 | <0.01 | |
| Geode Capital Management | $522,284.00 | 0.94 | 355,210 | -0.2% | -$1,033.66 | <0.0001 | |
| BlackRock | $502,348.00 | 0.91 | 341,733 | -21.27% | -$135,747.28 | <0.0001 | |
| Yakira Capital Management Inc | $295,375.00 | 0.53 | 200,935 | 0% | +$0 | 0.01 | |
| Squarepoint Ops LLC | $219,734.00 | 0.4 | 149,479 | +405.61% | +$176,274.95 | <0.01 | |
| Ubs Oconnor Llc | $208,345.00 | 0.38 | 141,731 | -25.2% | -$70,172.07 | 0.02 | |
| Wealth Effects Llc | $168,315.00 | 0.3 | 114,500 | -2.55% | -$4,410.00 | 0.03 | |
| State Street | $156,011.00 | 0.28 | 106,130 | 0% | +$0 | <0.0001 | |
| Northern Trust | $153,453.00 | 0.28 | 104,390 | -5.9% | -$9,613.78 | <0.0001 | |
| Stonepine Capital Management Llc | $140,586.00 | 0.25 | 95,637 | -92.94% | -$1.85M | 0.11 | |
| Jane Street Capital | $137,767.00 | 0.25 | 93,719 | New | +$137,767.00 | <0.0001 | |
| Empowered Funds Llc | $129,969.00 | 0.23 | 88,414 | +8.13% | +$9,775.53 | <0.01 | |
| Corsair Capital Management LP | $69,672.00 | 0.13 | 47,396 | New | +$69,672.00 | 0.02 | |
| Millennium Management LLC | $61,337.00 | 0.11 | 41,726 | -19.31% | -$14,682.31 | <0.0001 | |
| Chicago Partners Wealth Advisors | $58,681.00 | 0.1 | 37,859 | -27.66% | -$22,432.98 | <0.01 | |
| BNY Mellon | $51,535.00 | 0.09 | 35,058 | -13.56% | -$8,083.49 | <0.0001 | |
| Morgan Stanley | $37,933.00 | 0.07 | 25,805 | +64.36% | +$14,854.21 | <0.0001 | |
| Gsa Capital Partners Llp | $35,000.00 | 0.06 | 23,493 | -36.65% | -$20,250.93 | <0.01 | |
| Simplicity Wealth Llc | $29,400.00 | 0.05 | 20,000 | New | +$29,400.00 | <0.01 | |
| Bleakley Financial Group Llc | $29,400.00 | 0.05 | 20,000 | 0% | +$0 | <0.01 | |
| Raymond James Associates | $25,569.00 | 0.05 | 17,394 | -5.95% | -$1,616.99 | <0.0001 | |
| Hrt Financial Llc | $24,000.00 | 0.05 | 16,924 | New | +$24,000.00 | <0.0001 | |
| Tower Research Capital | $24,310.00 | 0.04 | 16,537 | +225.28% | +$16,836.33 | <0.0001 | |
| O Shaughnessy Asset Management Llc | $22,584.00 | 0.04 | 15,363 | -59.3% | -$32,902.11 | <0.0001 | |
| Dimensional Fund Advisors | $22,046.00 | 0.04 | 14,997 | 0% | +$0 | <0.0001 | |
| Susquehanna International Group | $21,841.00 | 0.04 | 14,858 | -75.85% | -$68,586.44 | <0.0001 | |
| Park Avenue Securities Llc | $21,000.00 | 0.04 | 14,000 | 0% | +$0 | <0.0001 | |
| Virtu Financial Llc | $20,000.00 | 0.04 | 13,633 | New | +$20,000.00 | <0.01 | |
| Tfb Advisors Llc | $20,817.00 | 0.03 | 12,103 | +1.34% | +$275.20 | 0.01 | |
| Flagship Harbor Advisors | $18,008.00 | 0.03 | 12,250 | -30.99% | -$8,085.22 | <0.01 | |
| Simplex Trading Llc | $14,000.00 | 0.03 | 10,086 | -4.41% | -$645.45 | <0.0001 | |
| PDS Planning, Inc. | $14,700.00 | 0.03 | 10,000 | New | +$14,700.00 | <0.01 | |
| Sageview Advisory Group Llc | $738,531.00 | 0.02 | 9,070 | New | +$738,531.00 | <0.01 | |
| Wells Fargo | $9,034.00 | 0.02 | 6,145 | +0.08% | +$7.35 | <0.0001 | |
| Sandy Spring Bank | $7,350.00 | 0.01 | 5,000 | New | +$7,350.00 | <0.0001 | |
| Fidelity Investments | $6,222.00 | 0.01 | 4,232 | New | +$6,222.00 | <0.0001 | |
| Advisor Group Holdings Inc | $4,851.00 | 0.01 | 3,300 | 0% | +$0 | <0.0001 | |
| U.S. Bancorp | $4,557.00 | 0.01 | 3,100 | 0% | +$0 | <0.0001 | |
| Qube Research & Technologies | $3,798.00 | 0.01 | 2,584 | -55.93% | -$4,819.52 | <0.0001 | |
| FinTrust Capital Advisors, LLC | $3,087.00 | 0.01 | 2,100 | 0% | +$0 | <0.01 | |
| LAZARD ASSET MANAGEMENT LLC | $2,000.00 | <0.01 | 1,592 | -9.9% | -$219.85 | <0.0001 |